Gupta, 2,215 patient HCQ late treatment study: 6% higher mortality [p=0.41] https://c19p.org/gupta
copied to clipboard
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
et al., JAMA Intern. Med., doi:10.1001/jamainternmed.2020.3596
Analysis of 2215 intensive care unit patients showing no significant differences with this very late stage use of HCQ. HCQ+AZ mortality relative risk RR 0.96, p=0.53, HCQ and HCQ+AZ combined RR 1.06, p=0.409.
|
risk of death, 6.0% higher, RR 1.06, p = 0.41, treatment 631 of 1,761 (35.8%), control 153 of 454 (33.7%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
very late stage, >50% on oxygen/ventilation at baseline.
Gupta et al., 7/15/2020, retrospective, USA, North America, peer-reviewed, baseline oxygen required 87.1%, 34 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.